Skip to main content
Top
Published in: AIDS Research and Therapy 1/2024

Open Access 01-12-2024 | Human Immunodeficiency Virus | Case Report

Missed opportunities for HIV testing and sexual health-related challenges in an individual with intellectual disability: a case report

Authors: Lina Martina Würfel, Anja Potthoff, Sandeep Nambiar, Adriane Skaletz-Rorowski

Published in: AIDS Research and Therapy | Issue 1/2024

Login to get access

Abstract

Background

HIV testing remains an important tool in identifying people living with HIV/AIDS (PLWHA). An early diagnosis of HIV can lead to a prolonged life expectancy if treatment is initiated promptly. Indicator conditions can be the first sign of an HIV infection and should therefore be recognised and consequently a HIV test should be carried out. Testing should occur in all individuals as sexuality can be experienced by everyone, and stigma can lead to the exclusion of vulnerable groups, leading to a gap in diagnosis and treatment [1, 2].

Case presentation

A 63-year-old man, who identifies as bisexual and has had an intellectual disability since birth, presented at our health care centre for HIV testing. A decade ago, the patient was diagnosed with Stage III Diffuse Large B-cell Non-Hodgkin Lymphoma, an AIDS defining cancer. The patient presented at a Haematology and Oncology department 3 months prior, due to a weight loss of 10 kg over the past 5 months. Oral thrush, an HIV-indicator condition, had been diagnosed by the otolaryngologists shortly before. During this medical evaluation, pancytopenia was identified. Despite the presence of indicator conditions, the patient was never tested for HIV in the past. Staff members from the care facility for intellectually disabled suggested conducting a HIV test in our clinic through the public health department, where HIV positivity was revealed. The AIDS-defining diagnosis, along with a CD4 + cell count of 41/µl, suggests a prolonged period of HIV positivity.

Conclusion

Due to the presence of existing indicator conditions, an earlier HIV diagnosis was possible. We contend that most of the recent illnesses could have been prevented if earlier testing had been carried out. Therefore, patients presenting with AIDS indicator conditions, including those with mental disabilities, should be given the opportunity to be tested for HIV. HIV/AIDS trainings should be made available to health care professionals as well as to personnel interacting with vulnerable groups.
Literature
1.
go back to reference Jordans CCE, Vasylyev M, Rae C, Jakobsen ML, Vassilenko A, Dauby N et al. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review. Euro Surveill. 2022;27(48). Jordans CCE, Vasylyev M, Rae C, Jakobsen ML, Vassilenko A, Dauby N et al. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review. Euro Surveill. 2022;27(48).
3.
go back to reference Vaz-Pinto I, Gorgulho A, Esteves C, Guimarães M, Castro V, Carrodeguas A, Medina D. Increasing HIV early diagnosis by implementing an automated screening strategy in emergency departments. HIV Med. 2022;23(11):1153–62.CrossRefPubMedPubMedCentral Vaz-Pinto I, Gorgulho A, Esteves C, Guimarães M, Castro V, Carrodeguas A, Medina D. Increasing HIV early diagnosis by implementing an automated screening strategy in emergency departments. HIV Med. 2022;23(11):1153–62.CrossRefPubMedPubMedCentral
5.
go back to reference Bull L, Rayment M. HIV-indicator-condition-driven HIV testing: clinically effective but still rarely implemented. Clin Med (Lond). 2016;16(2):175–9.CrossRefPubMed Bull L, Rayment M. HIV-indicator-condition-driven HIV testing: clinically effective but still rarely implemented. Clin Med (Lond). 2016;16(2):175–9.CrossRefPubMed
6.
go back to reference Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, et al. Time from human immunodeficiency virus seroconversion to reaching CD4 + cell count thresholds < 200, <350, and < 500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011;53(8):817–25.CrossRefPubMed Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, et al. Time from human immunodeficiency virus seroconversion to reaching CD4 + cell count thresholds < 200, <350, and < 500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011;53(8):817–25.CrossRefPubMed
7.
go back to reference Deffew A, Coughlan B, Burke T, Rogers E. Staff member’s views and attitudes to supporting people with an intellectual disability: a multi-method investigation of intimate relationships and sexuality. J Appl Res Intellect Disabil. 2022;35(4):1049–58.CrossRefPubMed Deffew A, Coughlan B, Burke T, Rogers E. Staff member’s views and attitudes to supporting people with an intellectual disability: a multi-method investigation of intimate relationships and sexuality. J Appl Res Intellect Disabil. 2022;35(4):1049–58.CrossRefPubMed
8.
go back to reference Nyblade L, Stockton MA, Giger K, Bond V, Ekstrand ML, Lean RM, et al. Stigma in health facilities: why it matters and how we can change it. BMC Med. 2019;17(1):25.CrossRefPubMedPubMedCentral Nyblade L, Stockton MA, Giger K, Bond V, Ekstrand ML, Lean RM, et al. Stigma in health facilities: why it matters and how we can change it. BMC Med. 2019;17(1):25.CrossRefPubMedPubMedCentral
9.
go back to reference Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A. Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. Aids. 2014;28(2):257–65.CrossRefPubMed Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A. Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. Aids. 2014;28(2):257–65.CrossRefPubMed
10.
go back to reference Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. Aids. 2019;33(9):1411–20.CrossRefPubMed Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. Aids. 2019;33(9):1411–20.CrossRefPubMed
11.
go back to reference Deblonde J, De Koker P, Hamers FF, Fontaine J, Luchters S, Temmerman M. Barriers to HIV testing in Europe: a systematic review. Eur J Public Health. 2010;20(4):422–32.CrossRefPubMed Deblonde J, De Koker P, Hamers FF, Fontaine J, Luchters S, Temmerman M. Barriers to HIV testing in Europe: a systematic review. Eur J Public Health. 2010;20(4):422–32.CrossRefPubMed
12.
go back to reference Mangurian C, Cournos F, Schillinger D, Vittinghoff E, Creasman JM, Lee B, et al. Low rates of HIV Testing among adults with severe Mental illness receiving care in Community Mental Health settings. Psychiatr Serv. 2017;68(5):443–8.CrossRefPubMed Mangurian C, Cournos F, Schillinger D, Vittinghoff E, Creasman JM, Lee B, et al. Low rates of HIV Testing among adults with severe Mental illness receiving care in Community Mental Health settings. Psychiatr Serv. 2017;68(5):443–8.CrossRefPubMed
Metadata
Title
Missed opportunities for HIV testing and sexual health-related challenges in an individual with intellectual disability: a case report
Authors
Lina Martina Würfel
Anja Potthoff
Sandeep Nambiar
Adriane Skaletz-Rorowski
Publication date
01-12-2024

Other articles of this Issue 1/2024

AIDS Research and Therapy 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine